June 08, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Three dosing levels of enpatoran each reduced disease activity among patients with skin manifestations of cutaneous or systemic lupus erythematosus, according to data published in Lancet Rheumatology.“The connection between interferon and SLE is an old story going back to the 1970s, when Hooks and his colleagues at the NIH published in the New England Journal of Medicine the results of
June 08, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Novel Lupus Drugs Continue to Shine in Extended Early Data

AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

Groundbreaking therapy could revolutionise treatment for lupus

Can Hydroxychloroquine Reduce Risk of Progression to SLE in Patients With Incomplete Lupus?

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Novel Concept, 'Immune Dimming,' Explored in Rheumatoid Arthritis

For one of the two, the benefits continue long after treatment stops

DESTIN, Fla. — New treatments have improved outcomes in lupus, but preventing disease in the early stages remains elusive,…

CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the…

AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026

A novel NLRP3 inhibitor reduced high-sensitivity C-reactive protein and other inflammatory biomarkers in patients at high…

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death